Newbury Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Newbury Pharmaceuticals's earnings have been declining at an average annual rate of -29.3%, while the Pharmaceuticals industry saw earnings growing at 8.6% annually. Revenues have been growing at an average rate of 76.4% per year.
Key information
-29.3%
Earnings growth rate
-13.9%
EPS growth rate
Pharmaceuticals Industry Growth | 30.5% |
Revenue growth rate | 76.4% |
Return on equity | -43.7% |
Net Margin | -118.2% |
Next Earnings Update | 09 Oct 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Newbury Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 May 24 | 19 | -22 | 27 | 0 |
29 Feb 24 | 23 | -17 | 24 | 0 |
30 Nov 23 | 21 | -17 | 23 | 0 |
31 Aug 23 | 10 | -19 | 21 | 0 |
31 May 23 | 12 | -19 | 20 | 0 |
28 Feb 23 | 7 | -18 | 18 | 0 |
30 Nov 22 | 6 | -17 | 16 | 0 |
31 Aug 22 | 6 | -15 | 15 | 0 |
31 May 22 | 3 | -13 | 13 | 0 |
28 Feb 22 | 3 | -12 | 11 | 0 |
30 Nov 21 | 3 | -10 | 9 | 0 |
31 Aug 21 | 3 | -6 | 6 | 0 |
Quality Earnings: NEWBRY is currently unprofitable.
Growing Profit Margin: NEWBRY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NEWBRY's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NEWBRY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NEWBRY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: NEWBRY has a negative Return on Equity (-43.74%), as it is currently unprofitable.